Figure 7
Comparison of in vivo antitumor effects of BT942 with daclizumab or combination of BT942 and anti-mouse PD1 antibody (n = 8). (a) Mean tumor growth volumes in different treatment groups. Mice were injected by BT942, Daclizumab (Sansheng Guojian), anti-mouse PD1, their combination of BT942 and anti-mouse PD1 antibody or vehicle (PBS) when mean tumor volumes reached 68 mm3 at day 5. Tumor size was measured twice a week by caliper. p values obtained by two-way ANOVA. (b–l) Quantification of CD45+, CD3+, CD8+, CD8+Granzyme B+, CD8+Ki67+, CD4+T, CD4+Teff (CD4+FoxP3−), CD4 +Teff Granzyme B+ (CD4+FoxP3−Granzyme B+), CD4 +Teff Ki67+ (CD4+FoxP3−Ki67+), hCD25+Foxp3+ and Foxp3+ (Treg) cell population percentage in live cells in MC38 tumors. p values obtained by one-way ANOVA. Bars without labels indicate that no statistical significance was observed. (m) CD8+/Treg cell ratios were analyzed. p values obtained by one-way ANOVA. Bars without labels indicate that no statistical significance was observed. Data were presented as mean ± SEM.
